Education
About Us
Working with TipRanks
Follow Us
Cooper Co (DE:CP60)
FRANKFURT:CP60
CP60 Stock Chart & Stats
€59.50
€0.45(0.51%)
At close: 4:00 PM EST
€59.50
€0.45(0.51%)
Day’s Range― - ―
52-Week Range€54.00 - €99.20
Previous CloseN/A
Volume200.00
Average Volume (3M)27.00
Market Cap
$11.86B
Enterprise Value€16.49B
Total Cash (Recent Filing)$124.90M
Total Debt (Recent Filing)$2.48B
Price to Earnings (P/E)32.0
Beta0.53
Next Earnings
Dec 04, 2025EPS Estimate
0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.95
Shares Outstanding198,808,910
10 Day Avg. Volume0
30 Day Avg. Volume27
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue4.08
Enterprise Value/Gross Profit6.09
Enterprise Value/Ebitda15.12
Forecast
1Y Price Target
$70.45Price Target Upside18.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Company ValuationA separation of the CVI and CSI businesses is seen as feasible with current company valuations, presenting an opportunity for a strategic split.
Strategic InitiativesThe evaluation of strategic alternatives, including the separation of its Contact Lens and Women’s Health businesses, is seen as potentially value creative for investors.
Bears Say
Financial PerformanceManagement lowered FY25 revenue guidance, and the new guidance is notably below the Street's expectations.
Market TrendsA general downward trend is observed in large cap MedTech stocks, which could impact Cooper Companies.
Regulatory ChallengesSignificant regulatory hurdles are expected for the acquisition of Bausch & Lomb’s Contact Lens business, raising concerns over industry concentration.
Cooper Co News
CP60 FAQ
What was Cooper Co’s price range in the past 12 months?
Cooper Co lowest stock price was €54.00 and its highest was €99.20 in the past 12 months.
What is Cooper Co’s market cap?
Cooper Co’s market cap is $11.86B.
When is Cooper Co’s upcoming earnings report date?
Cooper Co’s upcoming earnings report date is Dec 04, 2025 which is in 25 days.
How were Cooper Co’s earnings last quarter?
Cooper Co released its earnings results on Aug 27, 2025. The company reported €0.951 earnings per share for the quarter, beating the consensus estimate of €0.921 by €0.029.
Is Cooper Co overvalued?
According to Wall Street analysts Cooper Co’s price is currently Undervalued.
Does Cooper Co pay dividends?
Cooper Co does not currently pay dividends.
What is Cooper Co’s EPS estimate?
Cooper Co’s EPS estimate is 0.96.
How many shares outstanding does Cooper Co have?
Cooper Co has 198,808,910 shares outstanding.
What happened to Cooper Co’s price movement after its last earnings report?
Cooper Co reported an EPS of €0.951 in its last earnings report, beating expectations of €0.921. Following the earnings report the stock price went down -14.844%.
Which hedge fund is a major shareholder of Cooper Co?
Currently, no hedge funds are holding shares in DE:CP60
Cooper Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.45 (18.40% Upside)
$70.45 (18.40% Upside)
Blogger Sentiment
Bullish
DE:CP60 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.15%
12-Months-Change
Fundamentals
Return on Equity
5.01%
Trailing 12-Months
Asset Growth
2.22%
Trailing 12-Months
Company Description
Cooper Co
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
CP60 Company Deck
CP60 Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call demonstrated robust free cash flow and strong performance in the EMEA region, alongside significant developments in the MyDay product line. However, there were notable challenges with revenue coming in below expectations due to a decline in Clarity orders and weakness in the Asia Pac e-commerce segment. The sentiment is balanced with positive prospects for MyDay and Myopia management but weighed down by immediate revenue challenges.View all DE:CP60 earnings summariesCP60 Net sales Breakdown
66.99% CooperVision
33.01% CooperSurgical
CP60 Stock 12 Month Forecast
Average Price Target
€70.45
▲(18.40% Upside)
Technical Analysis
AptarGroup
―
Baxter International
―
Hologic
―
Masimo
―
West Pharmaceutical Services
―
Options Prices
Currently, No data available
---